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Abstract 
Neuregulin 1 (NRG1) is a multifunctional and versatile protein: its numerous isoforms can signal in 
a paracrine, autocrine or juxtacrine manner,  playing a fundamental role during the development 
of the peripheral nervous system and during the process of nerve repair, suggesting that the 
treatment with NRG1 could improve functional outcome following injury. Accordingly, the use of 
NRG1 in vivo has already yielded encouraging results.  
The aim of this review is to focus on the role played by the different NRG1 isoforms during 
peripheral nerve regeneration and remyelination and to identify good candidates to be used for 
the development of tissue engineered medical devices delivering NRG1, with the final goal to 
promote better nerve repair. 
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Introduction to Neuregulin 1 
Neuregulins are a family of soluble and transmembrane growth factors encoded by four different 
genes. Among them, the most studied is Neuregulin 1 (NRG1) which is involved in the 
development of heart, mammary gland, brain and nerve through the activation of different 
combinations of the tyrosine kinase receptors ErbB2, ErbB3 and ErbB4 (Mei & Xiong, 2008; Yarden 
& Sliwkowski, 2001). NRG1 plays an important role in myelination and peripheral nerve 
regeneration, and  - for this reason – was the main subject of recent comprehensive reviews, to 
which this review will refer also for the references that for space limits have not been cited here 
(Fricker & Bennett, 2011; Nave & Salzer, 2006; Pereira, Lebrun-Julien, & Suter, 2012; Salzer, 2012; 
Syed & Kim, 2010; Taveggia, Feltri, & Wrabetz, 2010).  
This review aims to give an overview of what is known about the role of NRG1 in axonal growth,  
myelination and re-myelination, focusing the attention on its prospective clinical application to 
promote peripheral nerve regeneration, taking into consideration the different possible delivery 
systems.  
 
Neuregulin1 gene products 
Over time, different NRG1 isoforms were identified and named according to the context in which 
they were found (neu differentiation factor/NDF, heregulin/HRG, acetylcholine receptor-inducing 
activity/ARIA, glial growth factor/GGF, sensory and motor neuron-derived factor/SMDF), until all 
of them were recognized to belong to the same gene, and named neuregulin1/NRG1 (Falls, 2003; 
Marchionni et al., 1993).  
In this review, the different NRG1 isoforms will be named according to the scheme proposed and 
shared by different authors (Falls, 2003; Mei & Xiong, 2008), based on exon composition (Figure 
1). NRG1 is encoded by a gene spanning 2,6 mbp in humans and rats, 2,4 mbp in mice (Chou & 
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Ozaki, 2010). All NRG1 isoforms contain an epidermal growth factor (EGF)-like domain that is 
located in the extracellular portion of the protein and is necessary and sufficient for the receptor 
activation.  
Six types of NRG1 were described (I-VI), which differ for N terminal exons, arising from alternative 
splicing and use of alternative promoters. Type I (NDF/HRG/ARIA), II (GGF) and III (SMDF) are 
encoded in a wide range of vertebrate genomes, type IV appears to be restricted to mammalian, 
type V and VI appear to be restricted to primates (Chou & Ozaki, 2010).  
An immunoglobulin (Ig)-like domain – located between the N-terminal sequence and the EGF-like 
domain - characterizes NRG1 type I, II, IV and V (with or without a spacer region), whereas NRG1 
type III and VI present an N-terminal region connected directly to the EGF-like domain. In Type III 
NRG1 the N- and the C-terminal regions are both located inside the cell (except one isoform -
NRG1-type III-β3 - which presents inside the cell only the N-terminal). The type III N terminal 
sequence contains also a cystein-rich domain (CRD) with an additional transmembrane domain 
(TMn).  
The number (greater than 30) and the nomenclature of the identified NRG1 derives also from the 
alternative use of different exons located downstream the EGF-like domain: the first exon can be α 
or β or can be missing (γ); the following exon can be 1, or 4, or 3 (followed by a stop codon) or 
missing (isoform 2), the next exon is a transmembrane domain (TMc), followed by a cytoplasmic 
exon c, that can be followed by a stop codon (isoform c), by exon a or exon b.  The activity of β 
isoforms is 100 fold higher than that of α isoforms. 
Cleavage by the β-secretase BACE-1 (β-site of amyloid precursor protein-cleaving enzyme) or by 
the α-secretases TACE (tumour necrosis factor-α-converting enzyme) or ADAM (members of “a 
disintegrin and metalloprotease” family), generates soluble NRG1, except in the case of Type III 
NRG1, that remains trans-membrane.  As discussed in a following paragraph,  BACE-1 cleavage of 
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axonal NRG1-type III positively regulates myelination (Hu et al., 2006; Willem et al., 2006) and 
remyelination (Hu et al., 2008), while TACE cleavage has a negative effect on myelination (La 
Marca et al., 2011).  
Types IV- VI NRG1 are less characterized, but it is likely that they are processed like Types I- II (Mei 
& Xiong, 2008). 
The expression of the different isoforms is spatially and temporally regulated, suggesting that 
different isoforms display specific and unique characteristics. 
Different types of NRG1 I, II and III are expressed in the PNS; they activate – in cis and in trans - the 
heterodimeric receptor ErbB2/ErbB3 expressed by Schwann cells (SC). After ligand binding to 
ErbB3, ErbB3 and ErbB2 heterodimerize, ErbB2 tyrosine kinase switches on, and phosphorylates 
intracellular tyrosine residues which became docking sites for adaptor proteins involved in 
different signal transduction pathways, which eventually regulate the transcription of genes 
implicated in survival, migration, differentiation, proliferation and myelination (Fricker & Bennett, 
2011; Yarden & Sliwkowski, 2001) (and references therein).  
NRG1 is involved in many steps of the peripheral nerve development, playing a fundamental role 
in the development of SC precursors and in the interactions between axons (expressing mainly 
transmembrane NRG1-type III) and Schwann cells (expressing ErbB2-ErbB3 and soluble type I/II 
NRG1). The absence of NRG1-type III (Wolpowitz et al., 2000) or of the co-receptors ErbB3 
(Riethmacher et al., 1997) or ErbB2 (Morris et al., 1999; Woldeyesus et al., 1999) give rise to 
animals without or with severely reduced SC precursors; the absence of NRG1-type I/II give rise to 
normal SC (Meyer et al., 1997), suggesting that NRG1-type III is the most important isoform for SC 
development. Nevertheless, it has been shown - in the embryonic chick - that soluble NRG1 is also 
released by axons during the critical period of SC survival (Ma, Wang, Song, & Loeb, 2011).  
 7
 
- Figure 1 – 
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Legend to Figure 1 - NRG1 isoforms. Panel A - Six types of NRG1 are described (I-VI), which differ 
for N terminal exons. NRG1-type I, II, IV and V (with or without a spacer region) are characterized 
by an immunoglobulin (Ig)-like domain, located between the N-terminal sequence and the EGF-
like domain; NRG1-type III and VI present an N-terminal region connected directly to the EGF-like 
domain. The type III N- terminal sequence contains a cystein-rich domain (CRD) with an additional 
transmembrane domain (TMn). Variants derive also by splicing in the linker and in the cytoplasmic 
tail; the C-terminal transmembrane domain (TMc) is located  between these two regions. 
The great number of NRG1 isoforms derives also from the alternative use of different exons 
located downstream the EGF-like domain: the first exon can be α or β or can be missing (isoform 
γ); the second exon can be  1, or 4, or 3 (followed by a stop codon) or can be missing (isoform 2); 
the third exon can be a transmembrane domain (TMc), followed by a cytoplasmic exon c, that can 
be followed by a stop codon (isoform c), by exon a or exon b. 
Panel B - In this scheme is reported the structure of those isoforms (I, II and III, β1a and β3) cited 
in this review which is focused on peripheral nerve regeneration (see also Table I). Many soluble 
and mature NRG1 proteins are produced in the form of transmembrane precursors and are 
generated by the cleavage by  different secretases, except in the case of NRG1- β3 isoforms, which 
are already released as soluble mature proteins for autocrine/paracrine interactions (type I/II)  or 
as transmembrane mature proteins for juxtacruine interactions (type III).  
Panel C - NRG1-type III can be cleaved by α-secretases belonging to TACE (tumour necrosis factor-
α-converting enzyme) or ADAM (a disintegrin and metalloprotease) family (eg TACE/ADAM17) or 
by β-secretases (BACE-1/β-site of amyloid precursor protein-cleaving enzyme).  BACE-1 cleavage 
stimulates myelination (Hu et al., 2006; Willem et al., 2006) and remyelination (Hu et al., 2008), 
TACE cleavage inhibits myelination (La Marca et al., 2011) . A second cleavage by a γ-secretase 
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dependent protease, in those NRG1 isoforms containing the TMc,  generates a cytoplasmic 
fragment that can  translocate into the nucleus and influence gene transcription (Bao et al., 2004). 
For the contents of this figure, the authors got inspiration from different reviews and papers 
(Bao et al., 2003; Falls, 2003; La Marca et al., 2011; Mei & Xiong, 2008; Velanac et al., 2011).  
 
NRG1 isoforms and their role in Schwann cell myelination  
The existence of a signal instructing SC to deposit layers of myelin - the thickness of which is 
proportional to the diameter of the axon - had long been hypothesized. Transgenic and knock out 
mice (Table 1) allowed to demonstrate that neuronal NRG1-type III plays an instructive role on 
myelination, determining the ensheathment fate of axons: reduced NRG1 expression causes hypo-
myelination (Michailov et al., 2004; Taveggia et al., 2005), which can be rescued by lentiviral-
mediated expression of NRG1-type III-β1a (Taveggia et al., 2005).  Moreover, neuronal NRG1-type 
III has been shown to be required for remyelination and regeneration after nerve injury: single 
axons in which NRG1 has been ablated are hypomyelinated and regenerate more slowly (Fricker et 
al., 2011).    
Neuronal transmembrane NRG1-type III-β1a overexpression induces hyper-myelination (Michailov 
et al., 2004), converts unmyelinated axons of sympathetic neurons to myelination (Taveggia et al., 
2005), improves remyelination after peripheral nerve injury (Stassart et al., 2013).  
Neuronal NRG1-type III-β3 overexpression has no effect on myelin thickness (Gomez-Sanchez et 
al., 2009), but stimulates SC proliferation and enlarges peripheral nerve and ganglia.  
Neuronal soluble NRG1-type I-β1a overexpression does not alter myelination (Michailov et al., 
2004), but improves remyelination after peripheral nerve injury  (Stassart et al., 2013). These 
authors demonstrate that NRG1 produced by SC is not necessary for myelination, but it is strongly 
involved in remyelination, which is strongly impaired after nerve crush in mice lacking SC NRG1, 
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resulting in severe hypo-myelination. In these mice, the ectopic neuronal expression of NRG1-type 
I-β1a does not completely rescue for the absence of SC NRG1, suggesting that NRG1 released by 
SC is relevant for remyelination. This role is confirmed by the observation that NRG1-type I (both α 
and β isoforms) is strongly up-regulated following injury (Carroll, Miller, Frohnert, Kim, & Corbett, 
1997; Ronchi et al., 2013; Stassart et al., 2013). 
Intriguingly, Syed and colleagues (Syed et al., 2010) asked whether NRG1-type III - provided in a 
paracrine manner - would still promote myelination and they demonstrated that this is the case: a 
recombinant “soluble” (but containing all domains, including the CRD and the TMn domain) NRG1-
type III-β3 is able to promote in vitro myelination of dissociated dorsal root ganglia (DRG) neurons 
and of normally non myelinated superior cervical ganglion (SCG) neurons, and is able to rescue the 
myelination defects on Nrg1-typeIII 
+/-
 neurons (but not on Nrg1-typeIII 
-/-
 neurons). These data 
suggest that NRG1-typeIII must be expressed – even at low levels - as a transmembrane protein in 
order to allow early events of axonal segregation and ensheathment but, to further promote 
myelination, it can be delivered as a soluble protein.  
Then, they asked whether also the NRG1 concentration played a role on myelinating activity and 
they, amazingly, demonstrated that soluble Nrg1-typeII-β3 - when used at very low concentration 
- promotes myelination, while at higher concentration inhibit it, as previously shown by others 
(Zanazzi et al., 2001). Similarly, they demonstrated that “soluble” NRG1-type III – when used at 
high concentration - inhibits myelination (while at low concentration stimulates it). These data 
show that the concentration of soluble NRG1 (regardless of the isoform) plays an important role in 
determining the myelination fate of axons. Syed and colleagues demonstrate that there is a 
concentration threshold beyond which the AKT pathway is activated, playing a pro-myelinating 
effect, and a higher concentration threshold beyond which the ERK pathway is activated, leading 
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to myelination inhibition (and the thresholds are lower for NRG1-typeII, higher for “soluble” 
NRG1-typeIII).  
Following nerve injury, SC respond to axonal  damage up-regulating NRG1-type I/II (Carroll et al., 
1997; Ronchi et al., 2013; Stassart et al., 2013) and activating ERK signalling pathway (Harrisingh et 
al., 2004). Accordingly, it has been shown that activation of the ERK-signalling pathway in 
myelinating SC drives them back to a dedifferentiated state, that is reversible: as soon as ERK 
signal diminishes, SC respond to axonal signals and redifferentiate (Napoli et al., 2012). Indeed, 
when Mycobacterium leprae, the leprosy pathogen, binds to and activates ErbB2, it activates ERK 
pathway and demyelination (Tapinos, Ohnishi, & Rambukkana, 2006). On the contrary,  it has been 
recently shown that sustained activation of ERK in SC and oligodendrocytes stimulates myelin 
growth and increases myelin thickness (Ishii, Furusho, & Bansal, 2013).  To explain these different 
results, it has been suggested that ERK activation can be promyelinating or demyelinating, 
depending on the context, on the strength and on the duration of activation; it has been proposed 
that, during development, ERK activation promotes myelination, while its activation in 
differentiated SC promotes demyelination.   
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NRG1 cleavage and consequences on myelination activity 
 
All NRG1 are synthesized with the EGF like domain exposed to the extracellular environment 
(Figure 1). With the exception of the β3 isoforms - lacking the transmembrane domain (TMc) - 
which are produced as soluble or transmembrane proteins (Falls, 2003), ready to interact with 
their receptors, most NRG1 isoforms are synthesized as transmembrane precursor proteins and 
need a proteolytic cleavage to release a soluble ligand for paracrine/autocrine signals (all type 
isoforms, except type III) or to expose the EGF like domain toward the extracellular environment 
for juxtacrine interactions (isoform type III).  
As discussed above, axonal NRG1-type III regulates myelin sheath thickness (Michailov et al., 
2004), determines the ensheathment fate of axons (Taveggia et al., 2005), is required for 
remyelination (Fricker et al., 2011). NRG1-type III can be cleaved by α-secretases belonging to the 
ADAM family (eg TACE/ADAM17) or by the β-secretase BACE-1 (Figure 1, panel C).  BACE-1 
cleavage stimulates myelination (Hu et al., 2006; Willem et al., 2006) and remyelination (Hu et al., 
2008), ADAM cleavage inhibits myelination (La Marca et al., 2011).  
Moreover, it has been shown that in NRG1 isoforms containing the TMc and the cytoplasmic tail 
(all but the β3 isoforms) a second cleavage by a γ-secretase dependent protease  can occur 
following ligand-receptor interactions, to activate “reverse signalling” (Bao, Wolpowitz, Role, & 
Talmage, 2003). A cytoplasmic fragment is released, that can translocate into the nucleus and 
influence transcription (Bao et al., 2004). 
TACE/ADAM17 cleaves NRG1 in the exon “1”  a few aminoacids (3-6) upstream the cleavage site of 
BACE-1 (La Marca et al., 2011) and its  down-regulation leads to precocious- and hyper-
myelination, that is neuron-autonomous (indeed, TACE inactivation in SC does not alter 
myelination). These results suggest that TACE inhibits myelination by limiting the amount of 
functional axonal NRG1-typeIII.  
 14
It has been also demonstrated that ADAM10 cleaves NRG1 in the same region, although its down-
regulation in a co-culture system was unable to affect normal myelination (Luo et al., 2011).  
Conversely, BACE-1 inhibition impaired normal myelination (Luo et al., 2011) and neuronal 
overexpression of NRG1-typeIII-β1a
GIEF
, a recombinant protein designed to mimic BACE-1 
cleavage, induces hyper-myelination in vivo and is sufficient to restore myelination in NRG1-
typeIII
-/-
 sensory neurons (Velanac et al., 2011), suggesting that the C terminal domain - that is 
missing in NRG1-typeIII-β1a
GIEF
 recombinant protein - is not required for myelination. 
Nevertheless, NRG1-typeIII-β1a overexpression promotes myelination also in BACE-1
-/- 
mice, 
suggesting that BACE-1 promotes myelination, but is not essential for NRG1 processing and pro-
myelination activity (Velanac et al., 2011). 
It will be intriguing to understand how a few aminoacids in the NRG1-type III C terminus are able 
to guide the fate of axon myelination: NRG1-typeI-β1a cleaved by TACE or BACE-1 differ for a few 
Aminoacids; moreover, the C terminal aminoacids that characterize β3 are just 11 and, as 
previously mentioned, the neuronal overexpression of NRG1-typeIII-β3 does not induce hyper-
myelination (Gomez-Sanchez et al., 2009). As already discussed by Velanac et al., these 11 
aminoacids can serve as an acylation-like modification site, that tightly associate this isoform to 
the membrane (Cabedo, Luna, Fernandez, Gallar, & Ferrer-Montiel, 2002), likely activating 
different signalling pathway. On the other hand, β3 exon aminoacids are present in the isoform 
NRG1-typeII-β3 (GGF2) which is currently used for clinical trials and, provided at very low 
concentration, promotes myelination, at higher concentration inhibit it (Syed et al., 2010; Zanazzi 
et al., 2001). Understanding the role played by the “GIEF” aminoacids which remain following 
BACE-1 cleavage (Velanac et al., 2011), and by the β3 exon aminoacids, will contribute to 
understand the myelination process.  
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NRG1 to promote nerve repair  
Peripheral nerve injury and repair   
Axons in the adult peripheral nervous system (PNS) undergo spontaneous regeneration after 
injury. Following a peripheral nerve injury, the type of nerve repair depends on the length of the 
nerve gap between the proximal and the distal stump (Siemionow & Brzezicki, 2009), as shown in 
Figure 2. Short gaps (few mm), can be repaired by direct suture of the proximal and the distal 
stumps with end-to-end coaptation and epineural suturing. The most common treatment for 
longer nerve gaps is surgical repair using autologous nerve grafts (autografts) (Deumens et al., 
2010; Kandenwein, Kretschmer, Engelhardt, Richter, & Antoniadis, 2005). Autografts have shown 
high efficacy in inducing nerve regeneration because they provide to the regenerating axons a 
natural guidance channel with SC surrounded by their basal lamina, allowing appropriate 
alignment of outgrowing axons (Deumens et al., 2010). However, there are some drawbacks in 
using autografts: donor site morbidity and  sensory loss, scarring, neuroma formation and limited 
length of available graft material encouraging the search of alternatives for nerve gap 
reconstruction. On the other hand, current techniques and artificial nerve conduit devices 
available to support regeneration across large lesion gaps have limited success (Deumens et al., 
2010; Steed, Mukhatyar, Valmikinathan, & Bellamkonda, 2011). Allografts have been used, but 
immunosuppression is required and this technique results in poor success rates (Mackinnon & 
Dellon, 1990). Autologous and autogenous blood vessels (Chiu et al., 1988) and muscle fibres 
(Glasby, Gschmeissner, Hitchcock, & Huang, 1986)  have also been used as conduits for nerve 
regeneration with different success rates; however, they present the same disadvantages as auto 
and allografts  (Doolabh, Hertl, & Mackinnon, 1996).  In 1993, Brunelli et al. described a new 
biological conduit represented by a vein segment filled with fresh skeletal muscle (Brunelli, 
Battiston, Vigasio, Brunelli, & Marocolo, 1993). Both the vein and  the  skeletal muscle of this 
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autologous graft are withdrawn in the site of surgery and are sutured to bridge the two stumps of 
a severed nerve. The clinical use of this autologous device led to good results in terms of motor 
and sensory recovery in 85% of patients in which it was applied (Battiston, Tos, Cushway, & 
Geuna, 2000).  
Instead of autografts, artificial Nerve Guidance Channels (NGC) may be used to enhance 
regeneration avoiding availability and immune rejection problems (Kehoe, Zhang, & Boyd, 2012; 
Steed et al., 2011). The basic design are hollow tubes in which the proximal and the distal stumps 
of the injured nerve are inserted. More recently, research has been focused mainly on improving 
the single lumen nerve tube to bridge larger nerve gaps (de Ruiter, Malessy, Yaszemski, 
Windebank, & Spinner, 2009; de Ruiter, Spinner, Yaszemski, Windebank, & Malessy, 2009). The 
artificial conduit may be implanted empty, or it may be filled with collagen and laminin-containing 
gels (Labrador, Buti, & Navarro, 1998; Madison, Da Silva, & Dikkes, 1988; Verdu et al., 2002), 
internal frameworks (de Ruiter, Spinner et al., 2009; Francel, Francel, Mackinnon, & Hertl, 1997; 
Lundborg & Kanje, 1996; Meek et al., 2001; Nakamura et al., 2004; Yoshii & Oka, 2001; Yoshii, Oka, 
Shima, Taniguchi, & Akagi, 2003), supportive cells (Ansselin, Fink, & Davey, 1997; Evans et al., 
2002; Guenard, Kleitman, Morrissey, Bunge, & Aebischer, 1992; Kim et al., 1994; Rodriguez, Verdu, 
Ceballos, & Navarro, 2000; Sinis et al., 2005), growth factors (Derby et al., 1993; Fine, Decosterd, 
Papaloizos, Zurn, & Aebischer, 2002; Hollowell, Villadiego, & Rich, 1990; Lee et al., 2003; Midha, 
Munro, Dalton, Tator, & Shoichet, 2003; Sterne, Brown, Green, & Terenghi, 1997), and conductive 
polymers, but combinations have also already been used (Figure 2).  
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- Figure 2 - 
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Legend to figure 2 - Short gap versus long gap peripheral nerve injury. (A) Short gaps (< 2mm) can 
be directly repaired by suturing the proximal and the distal stumps one to each other without 
tension. (B) Longer gaps (> 2 mm) can be repaired by using autologous or artificial nerve grafts, 
also called Nerve Guidance Channels (NGC). Autologous grafts are: (C) nerve autograft ,  (D) blood 
vessel, (E) muscle fibre, (F) vein filled with muscle (muscle-vein combined conduit). Modifications 
of autologous grafts are:  (G) autograft infected with viruses, (H) vein filled with muscle infected 
with viruses.  
Artificial grafts can be: (I) empty artificial nerve graft, that can be used to repair gaps (2-10 mm); 
modifications to the lumen of empty artificial NGC may be helpful to repair longer gaps (> 20 mm): 
(J) internal framework-filled artificial NGC, (K) multichannel-filled artificial NGC, (L) sponge-filled 
artificial NGC, (M) filament-filled artificial NGC, (N) conductive artificial NGC, (O) artificial NGC 
incorporated with growth factors, (P) artificial NGC incorporated with supportive cells, (Q) artificial 
NGC incorporated with supportive cells and (R) growth factors and artificial NGC incorporated with 
virus infected supportive cells. 
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An artificial graft can meet many of the needs of regenerating fibres by concentrating 
neurotrophic factors, reducing cellular invasion and providing directional neuritis outgrowth to 
prevent neuroma formation. 
 
NRG1 isoform expression during nerve regeneration  
SC dedifferentiation and proliferation are a precondition for axonal regeneration in the lesioned 
peripheral nervous system (Carroll et al., 1997). The different NRG1 isoforms play an important 
role in this process, thanks to their ability to stimulate dedifferentiation, proliferation and 
differentiation of SC in vitro (Stassart et al., 2013). 
Many studies have examined the expression of the different NRG1 isoforms at various times 
following peripheral nerve injury. It has been reported that expression of NRG1-type I and -type II 
isoforms is induced after sciatic nerve transection (3-30 days post injury) and is strictly associated 
with SC, strengthening the idea that NRG1 acts not only by juxtacrine interactions, but also by 
autocrine/paracrine communication  (Carroll et al., 1997; Ronchi et al., 2013; Stassart et al., 2013). 
Interestingly, these authors reported that NRG1-typeII-β3 expression in SC coincides with the DNA 
synthesis phase and this expression lasts in spite of markedly diminished SC mitogenesis, rising the 
question whether SC could regulate mitosis in the presence of persistent NRG1.  
A rapid but transient  activation of the NRG1 receptor ErbB2 in myelinating SC after sciatic nerve 
axotomy was detected (Guertin, Zhang, Mak, Alberta, & Kim, 2005). The authors defined the role 
of this activation using an ErbB2 antagonist so preventing, in vivo, SC  response to axotomy and, in 
vitro, SC demyelination in neuron-SC co-cultures. Two days post-nerve injury, NRG1 receptors are 
strongly down-regulated (Ronchi et al., 2013); 4-5 days post-nerve injury,  when Wallerian 
degeneration and demyelination occur, ErbB2  is expressed and activated (Carroll et al., 1997; 
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Kwon et al., 1997). An earlier increase, at 3 days post injury, is observed for Erbin, an ErbB2 
interacting protein whose expression is required for remyelination (Liang et al., 2012). 
Indeed, the heterodimer receptor ErbB2-ErbB3 is co-ordinately induced in axotomized nerve SC, 
suggesting that the density of functional NRG1-receptors may modulate NRG1 activity during the 
process of peripheral nerve Wallerian degeneration.  
These results are in accordance with a previous study (Li, Terenghi, & Hall, 1997) in which 
chronically denervated SC were missing ErbB2. It was proposed that the lack of ErbB2 renders SC 
chronically insensitive to axonal derived NRG1, so contributing to the failure of axonal 
regeneration through chronically denervated distal nerve stumps. 
 Neuronal NRG1-type III, as previously discussed, plays an important role in myelination and nerve 
regeneration.  This isoform  is anchored to the axonal surface and directly communicates with 
adjacent glial cells. Recent studies have confirmed the actual importance  of the axon-derived 
NRG1 in nerve regeneration (Fricker et al., 2011). Through single-neuron labelling - by means of 
inducible Cre-mediated knock-out mice  (Young et al., 2008) - it was demonstrated that juxtacrine 
NRG1 signalling is not essential for maintenance of the myelin sheath and neuromuscular 
junctions, but it is necessary for the reparative response after nerve injury, including 
remyelination, axon regeneration, and reinnervation of the neuromuscular junctions. 
The NRG1 importance in the nerve regenerative process and in remyelination is more relevant 
when the functional outcome of non-nervous nerve grafts is analyzed. The analysis of a successful 
graft represented by a fresh muscle-vein-combined conduit (Geuna et al., 2007; Nicolino et al., 
2003; Tos et al., 2007) revealed that SC, in supporting axonal regeneration, very early and 
massively colonize the tubular graft migrating from both the proximal and the distal nerve stumps 
(Fornaro, Tos, Geuna, Giacobini-Robecchi, & Battiston, 2001; Raimondo et al., 2005). SC graft 
colonization is not only supported by migration from the nerve stumps, but also by active SC 
 21
proliferation accompanied by NRG1 up-regulation (Geuna et al., 2003). mRNA expression analysis 
of the early events occurring in this non-nervous tube placed to bridge a peripheral nerve gap has 
highlighted NRG1 α2 isoform - released by the muscle used to fill the tube - as suitable candidate 
to promote SC survival and activity in early post-operative phases, when regenerating axons are 
still not present. It has been proposed that this molecule may promote SC survival and 
differentiation rather than proliferation (Raabe, Clive, Neuberger, Wen, & DeVries, 1996). These 
results suggest that NRG1 α2 isoform plays a role in supporting early SC survival and activity in the 
absence of axons and provides a possible explanation for the observed effectiveness of the fresh 
muscle-vein-combined technique for nerve repair . 
 
Biomaterials and delivery system  
As discussed previously, several studies demonstrated that endogenous NRG1 is required for 
nerve repair, suggesting that the treatment with recombinant NRG1 could improve peripheral 
nerve regeneration and functional outcome following injury. Different strategies have been used 
to deliver NRG1: subcutaneous injection, protein release by biomaterials, transplantation of NRG1 
expressing cells and injection of adenoviruses coding for NRG1 (Table 2). 
NRG1 subcutaneus injection 
Treatment with 1 mg/kg NRG1-II-β3 (recombinant human glial growth factor 2) via subcutaneous 
injection promotes nerve regeneration and accelerates  functional recovery after rat sciatic nerve 
injury (Chen et al., 1998). Histological assessment shows less severe degeneration and earlier 
robust axon remyelination, with improvement in axon diameter and myelin thickness, in the 
treated group. Epinerium injection with 500ng “GGF” (heuregulin α, Sigma Aldrich) after rabbit 
facial nerve anastomosis results in high SC and glial cell proliferation and in better nerve 
regeneration (Yildiz et al., 2011). 
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NRG1 release by biomaterials 
The most promising approach for growth factor delivery to the site of nerve injury is to load 
growth factors directly into the conduit (Simon, Terenghi, Green, & Coulton, 2000; Sterne et al., 
1997; Whitworth, Dore, Green, & Terenghi, 1995). Alginate hydrogel provides a sustained and 
controlled release of neurotrophich factors in vitro and in vivo (Austin, Bower, Kurek, & Muldoon, 
1997; Ko, Dixit, Shaw, & Gitnick, 1995) and freeze-dryed alginate supports axonal regeneration 
across 50-mm gap in the cat sciatic nerve (Suzuki et al., 1999). Moreover, coating of alginate 
hydrogel with fibronectin, supports SC viability and neuronal regeneration (Mosahebi, Wiberg, & 
Terenghi, 2003). An ultrapure endotoxin-free low-viscosity alginate with high manuronic content 
was used for recombinant NRG-1-type II-β3 (human GGF2, CeNes Pharmaceutical USA) delivery in 
a poly 3-hydroxybutyrate (PHB) polymer conduit to repair 20mm and 40mm gaps in rabbit 
common peroneal nerve (Mohanna, Young, Wiberg, & Terenghi, 2003). The same authors 
demonstrated that NRG-1-type II-β3 addition significantly increased SC quantity, sustained axonal 
regeneration over short and long gaps in comparison with empty and alginate conduits and 
improved target muscle reinnervation (Mohanna, Terenghi, & Wiberg, 2005).  
Nerve conduits can be produced to have characteristics as similar as possible to the native nerve,  
by combining growth factors, aligned extracellular matrix and biomaterial filaments, improving the 
nerve conduit performance and ensuring better functional recovery after in vivo transplantation. 
In vitro oriented collagen and a combination of differentiation factors (NGF, NRG-1, TGF-β) induce 
SC alignment (Ribeiro-Resende, Koenig, Nichterwitz, Oberhoffner, & Schlosshauer, 2009). TGF-β 
stimulates α1αβ1 and α6β1 integrin expression and affects cell polarity (Rogister et al., 1993; 
Stewart, Turner, Jessen, & Mirsky, 1997); NRG1 increases N-cadherin expression (Gess et al., 
2008); at low concentration NRG1 accelerates SC migration (Meintanis, Thomaidou, Jessen, 
Mirsky, & Matsas, 2001), at high concentration increases proliferation via activation and 
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phosphorylation of the ErbB2/ErbB3 receptor (Porter, Clark, Glaser, & Bunge, 1986; Rosenbaum et 
al., 1997). Poly-ε-caprolacton (PCL) filaments induce pronounced SC alignment with a polarized 
expression of the cell adhesion molecule L1 similar to that seen in vivo in bands of Büngner after 
sciatic nerve crush in adult rats (Ribeiro-Resende et al., 2009). Integration of bioengineered bands 
of Büngner - which would guide axonal regrowth - and growth factors for the development of 
innovative nerve guide implants, may be a promising strategy to facilitate and accelerate axonal 
regeneration. 
Silicone implants containing matrigel, poly-L-lactic acid (PLLA) microfilaments and NRG1-type I-β1 
(human heuregulin-β1, R&D systems) have been used to bridge a 14 mm gap in adult rats (Cai, 
Peng, Nelson, Eberhart, & Smith, 2004). Microfilaments provide organized guidance channels that 
direct SC migration, enhance cable formation and axonal regeneration longitudinally across nerve 
stumps (Lundborg & Kanje, 1996; Ngo et al., 2003; Zhao, Lundborg, Danielsen, Bjursten, & Dahlin, 
1997). NRG1 treatment caused an increase in SC number by inducing proliferation by an autocrine 
mechanism (Carroll et al., 1997). Application of a low dose of NRG1 promotes SC migration and 
trophic factor release that support neuronal survival and regeneration (Mahanthappa, Anton, & 
Matthew, 1996). Implants containing NRG1 and microfilaments act synergistically inducing a 
significant improvement in the number and longitudinal organization of both SC and axons, 
leading to axonal regeneration and nerve repair (Cai et al., 2004).  
Transplantation of NRG1 expressing cells 
The transplantation of cultured cells, transfected to express growth factors, into bio-engineered 
conduits, may be used to improve nerve regeneration. Due to their role in peripheral nerve 
regeneration SC may be used as a tool to deliver growth factors. Adult stem cells from adipose 
tissue or bone marrow can be differentiated into a SC-like phenotype and used as SC replacements 
(Faroni et al., 2011). Transplantation of cultured SC (Magnaghi, Procacci, & Tata, 2009; Mosahebi, 
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Woodward, Wiberg, Martin, & Terenghi, 2001), bone marrow mesenchymal stem cells (MSC) 
(Tohill, Mantovani, Wiberg, & Terenghi, 2004) and adipose-derived regenerative cells (ADRC) 
(Suganuma et al., 2013) has been used to promote peripheral nerve regeneration.   
In vitro, MSC exposed to NRG-1-type II-β3 (human GGF2, CeNes Pharmaceutical USA) express s100 
and glial fibrillary acidic protein (Tohill et al., 2004). Following transplantation into 10 mm nerve 
conduits in the rat sciatic nerve, MSC maintained s100 expression and promote nerve 
regeneration (Tohill et al., 2004).  
ADRC in combination with type I collagen gel have been used to bridge 10 mm sciatic nerve gaps in 
Wistar rats (Suganuma et al., 2013). ADRC promote peripheral nerve regeneration not by 
differentiating into SC, but – probably – by secreting NRG1 and VEGFA factors that promote 
proliferation and migration of SC (Suganuma et al., 2013). 
These data suggest that NRG1 stimulates the proliferation of glial cells, inhibits apoptosis and 
facilitates repair and regeneration of injured nerves in the peripheral nervous system.  
NRG1 has been successfully used in combination with different kinds of supportive cells, also to 
repair spinal cord injury. SC transfected to express high levels of NRG1 (of a non specified isoform) 
have been implanted into rats with hemisection spinal cord injury (J. Zhang, Zhao, Wu, Li, & Jin, 
2010). Transfected SC secreted a large amount of NRG1 both in vitro and in vivo, which results - in 
vivo - in ErbB2-ErbB4 up-regulation in neurons and neuroglia cells. After transplantation, cells 
survived and migrated into the spinal cord injuried areas. Significant recovery of hemisection 
spinal cord injury was observed in the group of rats implanted with transfected SC expressing 
NRG1. These results suggest that SC expressing NRG1 can significantly improve the repair of spinal 
cord injury by up-regulating  ErbB receptor expression in the target cells, increasing proliferation 
of glial cells, and protecting neurons from apoptosis (J. Zhang et al., 2010). 
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Co-transplantation of BMSC with transfected SC expressing NRG1 (of a non specified isoform) into 
a rat model of spinal cord hemisection injuries, reduced the size of cystic cavities, promoted 
axonal regeneration and hind limb functional recovery in comparison with SC or BMSC 
transplantation alone or together (J. F. Zhang et al., 2011). This treatment could provide important 
insights into potential therapies of spinal cord hemisection injuries to improve functional recovery. 
Delivery of NRG1 with transfected supportive cells may be a promising strategy for the repair of 
both spinal cord and peripheral nerve. 
Injection of NRG1 coding viruses  
Gene therapy, using adeno-associated viral (AAV) vectors (Kaplitt et al., 1994) and lentiviral (LV) 
vectors (Naldini et al., 1996) may be a promising strategy to promote peripheral nerve 
regeneration (Hoyng, Tannemaat, De Winter, Verhaagen, & Malessy, 2011).  
Recombinant adenoviruses have been used to express NRG1 to improve axonal regeneration in 
the injured peripheral nervous system (Joung et al., 2010). Rats, injected into both proximal and 
distal stump of the sciatic nerve with a recombinant adenovirus expressing the EGFβ- domain of 
NRG1-type I, display an augmented expression of neurofilaments, GAP43 and S100 in the distal 
stump of the injury site and increased the length of regenerating axons leading to sensory and 
motor functions improvement (Joung et al., 2010). These results suggest a therapeutic potential 
for β-EGF-like domain of NRG1 in the treatment of peripheral nerve injury. 
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Conclusions 
When a peripheral nerve is severely injured, the use of an artificial conduit becomes necessary if 
the nerve gap is too long to be directly sutured, as an alternative to the autograft, that gives good 
results, but has some clinical drawbacks. It has been shown that SC of the nerve autograft and the 
muscle of the muscle-vein conduit release soluble NRG1 which contributes to the effectiveness of 
this approaches (Nicolino et al., 2003). The aim of this review is to get a clear view of the role 
played by NRG1 during peripheral nerve regeneration, to identify the right isoform to be delivered 
to the injured nerve by grafted artificial nerve guidance channels.  
NRG1-type III could be the candidate with the therapeutic potential to improve nerve repair: 
literature data demonstrate that axonal transmembrane NRG1 is required for remyelination and 
regeneration after nerve injury, while it is dispensable for myelin maintenance (Fricker & Bennett, 
2011; Fricker et al., 2011). However, exogenous axonal transmembrane expression implies the use 
of viruses, that present some problems and risks (toxicity, immune and inflammatory responses, 
gene control and targeting issues).  
An alternative strategy to increase the amount of NRG1-type III suitable to stimulate myelination, 
is the inhibition of those α-secretases (eg TACE/ADAM17, ADAM10), whose activity negatively 
interferes with NRG1, impairing myelination. Several TACE (tumour necrosis factor alpha 
converting enzyme) inhibitors have been developed for the treatment of rheumatoid arthritis and 
other inflammatory disorders  (Bahia & Silakari, 2010; DasGupta, Murumkar, Giridhar, & Yadav, 
2009), because tumour necrosis factor alpha is one of the most common pro-inflammatory 
cytokines involved in rheumatoid arthritis and in other autoimmune diseases. However, most of 
them have broad spectrum inhibitory activity for other matrix metalloproteases involved in other 
processes and are not suitable candidates for clinical trials. 
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Several authors demonstrated that different soluble isoforms of NRG1 (including a type III isoform 
provided as “soluble” recombinant protein) can improve remyelination after peripheral nerve 
injury (Tables 1 and 2), with an activity that is concentration and isoform dependent (Syed et al., 
2010). They demonstrated that soluble type III isoforms have pro-myelinating activity in a broad 
concentration range, while type II isoforms have pro-myelinating activity when supplied at very 
low concentration, below the threshold that stimulates ERK activation. Therefore, soluble NRG1 
could be the candidate with the therapeutic potential to improve nerve repair (Syed & Kim, 2010).  
However, because the pro-myelinating activity of NRG1 seems to depend also on the exons which 
are downstream the EGF-like domain (α, β, γ, 1, 3, 4, a, b, c…), it is important to understand which 
isoforms have been used by the different authors. Nevertheless, in many papers it is really difficult 
to find this information, because the authors call it “NRG1” or use the old nomenclature.  
One of these soluble isoforms, type II-β3 (often called “GGF2”), has recently completed the Phase 
1 of a clinical trial in patients with heart failure: Acorda Therapeutics is conducting a clinical 
program for GGF2 in heart failure, and preclinical development to treat peripheral nerve injury 
and stroke. Other groups performed a Phase II clinical trial to study the efficacy and the safety of 
recombinant human NRG1 in patients with chronic heart failure (Gao et al., 2010). 
It has been shown that after damage to peripheral nerve, the injured nerve reacts with a peak of 
production of soluble NRG1-type I/II (Carroll et al., 1997; Ronchi et al., 2013; Stassart et al., 2013), 
ERK and AKT pathway activation (Harrisingh et al., 2004; Napoli et al., 2012; Sheu, Kulhanek, & 
Eckenstein, 2000) - that in vitro can be activated either by soluble NRG1 (Syed et al., 2010) either 
by other factors - SC dedifferentiation and proliferation. Subsequently, NRG1 type I/II level 
decreases, ERK pathway is switched off, and  SC remyelinate  axons expressing  transmembrane 
NRG1-type III.  
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These data suggest that soluble NRG1-type I/II could be the candidate to improve nerve repair 
when there is a large lesion and endogenous SC are not enough to produce an adequate amount 
of NRG1. Therefore, when designing tissue engineered medical devices to bridge large gap injuries 
and deliver NRG1, it is essential to get an early release of highly concentrated soluble NRG1 to 
stimulate ERK pathways and SC dedifferentiation, followed by a late release of NRG1 at low 
concentration to stimulate AKT activation and remyelination.  
In addition to NRG1, other molecules are certainly involved in the regeneration process (Pereira et 
al., 2012; Taveggia et al., 2010);  it is expected that the regenerative research will go towards the 
concomitant use of different factors, to obtain synergistic effects and better outcome. 
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